• Course

1.5 hours

All audiences

Biosimilars in breast cancer - the next challenge

After this seminar, the attendants should be able to:

  • Acquire new understanding of the key facts that support biosimilar approval in the EU as applied to breast cancer therapy
  • Recognise biased trends of change in first line therapy
  • Advise how to implement biosimilars of monoclonal antibodies used in breast cancer.

Contributors:

Joao Goncalves, Hanne Rolighed Christensen, Rupert Bartsch

Accreditation

Accreditor credit Accreditation statement
BMJ and EAHP biosimilars breast cancer 0.15 credits, 1:30 hours This course (Biosimilars in breast cancer - the next challenge) is accredited to the combined value of the modules it contains. (Universal Activity Number (UAN): 0475-0000-19-032-H04-P)
BMJ and EAHP biosimilars breast cancer 0.15 credits, 1:30 hours This course (Biosimilars in breast cancer - the next challenge) is accredited to the combined value of the modules it contains. (Universal Activity Number (UAN): 0475-0000-19-032-H04-P)

Release date

14 Feb 2019